A Phase II study of carboplatin and docetaxel followed by epstein-barr virus specific cytotoxic T Lymphocytes for refractory/relapsed EBV-positive nasopharyngeal carcinoma

      Almost all nonkeratinizing and undifferentiated nasopharyngeal carcinomas (NPC) are associated with Epstein Barr virus (EBV) infection. Historically, those with metastatic disease have a median survival of <1 year. Due to the poor prognosis and strong association with EBV in advanced stage disease, adoptive immunotherapy with EBV-specific cytotoxic T lymphocytes (EBV-CTLs) is an attractive therapeutic option. We and others have shown that EBV-CTL administration is feasible, safe and results in anti-tumor activity. While complete responses were obtained, those with bulky disease were more resistant to CTL therapy. We propose that EBV-CTL efficacy can be improved in relapsed/refractory NPC by using re-induction chemotherapy to decrease tumor burden prior to adoptive transfer.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Cytotherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect